Regeneron Pharmaceuticals
777 Old Saw Mill River Road, Tarrytown, NY 10523
Related Posts:
Regeneron to present at J.P. Morgan Healthcare Conference in January 2026
December 22, 2025
Regeneron Pharmaceuticals, Inc. announced it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
Read more →
Regeneron partners with Tessera on gene therapy program targeting alpha-1 antitrypsin deficiency
December 1, 2025
Regeneron Pharmaceuticals and Tessera Therapeutics have announced a global partnership to develop and commercialize TSRA-196, an investigational gene editing therapy aimed at treating alpha-1 antitrypsin deficiency (AATD).
Read more →
FDA approves new dosing options for Regeneron’s Eylea HD injection
November 19, 2025
Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for treating patients with macular edema following retinal vein occlusion (RVO).
Read more →
Regeneron reports positive phase 2 results for novel factor XI antibodies in knee surgery
November 8, 2025
Regeneron Pharmaceuticals has released results from two Phase 2 clinical trials that evaluated the antithrombotic effects of its investigational factor XI antibodies, REGN7508Cat and REGN9933A2, in patients undergoing total knee replacement surgery.
Read more →
Regeneron to participate in multiple healthcare investor conferences in late 2025
November 3, 2025
Regeneron Pharmaceuticals, Inc. announced that members of its management team will participate in several upcoming investor conferences in November and December 2025.
Read more →
Regeneron’s gene therapy shows sustained improvement in children with genetic hearing loss
October 12, 2025
Nearly all children participating in a clinical trial for Regeneron Pharmaceuticals' investigational gene therapy DB-OTO experienced significant improvements in hearing, according to new data published in The New England Journal of Medicine and...
Read more →
Regeneron Pharmaceuticals schedules Q3 2025 earnings release and conference call
September 30, 2025
Regeneron Pharmaceuticals, Inc. has announced it will release its financial and operating results for the third quarter of 2025 on October 28, prior to the opening of U.S. financial markets.
Read more →
FDA approves Regeneron’s Evkeeza for children aged one year or older with ultra-rare cholesterol disorder
September 26, 2025
Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Evkeeza (evinacumab-dgnb), an ANGPTL3 antibody, for use in children as young as one year old with homozygous familial hypercholesterolemia (HoFH).
Read more →
Regeneron reports new clinical trial data on obesity drug combinations
September 17, 2025
Regeneron Pharmaceuticals has released updated 26-week results from its Phase 2 COURAGE trial, which is studying the effects of combining semaglutide, a GLP-1 receptor agonist, with trevogrumab and garetosmab in patients with obesity.
Read more →Trending
The Weekly Newsletter
Sign-up for the Weekly Newsletter from Lohud Commercial.